Tizanidine Hydrochloride Capsule, Gelatin Coated
Product Images NDC 0591-2789

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 0591-2789). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (Image 1)

Structural Formula (Image 1)
FDA Label Image

Figure 1: Mean Tizanidine Concentration Vs. Time Profiles For Tizanidine Hydrochloride Tablets And Capsules (2 × 4 mg) Under Fasted And Fed Conditions (Image 2)

Figure 1: Mean Tizanidine Concentration Vs. Time Profiles For Tizanidine Hydrochloride Tablets And Capsules (2 × 4 mg) Under Fasted And Fed Conditions (Image 2)
FDA Label Image

Figure 2: Single Dose Study—mean Change In Muscle Tone From Baseline As Measured By The Ashworth Scale ± 95% Confidence Interval (a Negative Ashworth Score Signifies An Improvement In Muscle Tone From Baseline) (Image 3)

Figure 2: Single Dose Study—mean Change In Muscle Tone From Baseline As Measured By The Ashworth Scale ± 95% Confidence Interval (a Negative Ashworth Score Signifies An Improvement In Muscle Tone From Baseline) (Image 3)
FDA Label Image

Figure 3: Seven Week Study—mean Change In Muscle Tone 0.5–2.5 Hours After Dosing As Measured By The Ashworth Scale ± 95% Confidence Interval (a Negative Ashworth Score Signifies An Improvement In Muscle Tone From Baseline) (Image 4)

Figure 3: Seven Week Study—mean Change In Muscle Tone 0.5–2.5 Hours After Dosing As Measured By The Ashworth Scale ± 95% Confidence Interval (a Negative Ashworth Score Signifies An Improvement In Muscle Tone From Baseline) (Image 4)
This text is describing an improvement in the Ashworth Score. However, the context and details are not available.*
FDA Label Image

1 (Image 5)

1 (Image 5)
Tizanidine Hydrochloride Capsules contains 2.29 mg of tizanidine hydrochloride which is equivalent to 10 2 mg of tizanidine base. Manufactured by Teva, it is not interchangeable with tizanidine tablets or Zanaflex tablets. It's sold in a package that contains 150 capsules with RX only prescription. Keep the medication out of reach of children and store at a controlled room temperature. For more information on usage, the package insert should be referenced.*
FDA Label Image

1 (Image 6)

1 (Image 6)
Tizanidine Hydrochloride Capsules contains 4.58 mg of tizanidine hydrochloride, equivalent to 104 mg of tizanidine base. It is manufactured by Teva Pharmaceuticals USA, Inc. and should not be interchanged with tizanidine tablets or Zanaflex tablets. It is available in 150 capsules and should be stored at the USP Controlled Room Temperature. For more information, it is recommended to refer to the package insert for prescribing instructions. It is an Rx-only drug and should be kept out of the reach of children.*
FDA Label Image

1 (Image 7)

1 (Image 7)
Tizanidine Hydrochloride capsules are manufactured by Teva Pharmaceuticals USA, and each capsule contains 6.87mg tizanidine hydrochloride, which is equivalent to 106mg tizanidine base. They come in packages containing 150 capsules and are not interchangeable with tizanidine or Zanaflex tablets. It is a prescription drug and should be dispensed in containers with child-resistant closures. A temperature range of 15-30°C (59-86°F) is permissible for storage in USP-controlled room temperature. For more information, refer to the package insert.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.